Keyword: Selecta Biosciences
The cuts come as Selecta seeks to eke out its cash reserves and advance a gout drug that disappointed investors in phase 2.
Curis moves up COO as CEO departs; Merck scraps mandatory retirement age to keep CEO Frazier; and Bayer’s Americas pharma head to be CEO at Selecta.
Bayer’s Carsten Brunn, was named the next president and CEO of Selecta Biosciences, following the Dec. 1 retirement of CEO Werner Cautreels.
Selecta Biosciences presented new data from its SEL-212 gout therapy, which has convinced it to soldier on to a phase 3 clinical program this year.
The biotech painted data from the trial as positive, but the outside world took a different view, sending Selecta’s stock down by more than 20%.
Selecta Biosciences expects to get Phase II data for its lead candidate with the $70 million it just raised in an IPO.
After a strong year with a string of deals and successful funding rounds to its name, Nanoparticle specialist Selecta Biosciences has filed for a $75 million initial public offering.